Curis to Present at the 2017 RBC Capital Markets Global Healthcare Conference
February 17 2017 - 4:30PM
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the
development and commercialization of innovative drug candidates for
the treatment of human cancers, today announced that Dr. Ali
Fattaey, President & Chief Executive Officer, will present at
the 2017 RBC Capital Markets Global Healthcare Conference on Feb.
22, 2017 at 8:00 a.m. EST in New York City.
A corresponding webcast of the presentation can
be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2017/76101119713.cfm
The webcast will be archived shortly after the live event and
will be available until May 24, 2017. It will also be
available for 30 days on the Investor Relations section of the
Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative and effective drug candidates for
the treatment of human cancers, including its lead development
candidate, CUDC-907 that is being investigated in clinical studies
in patients with lymphomas and solid tumors. Curis is also engaged
in a broad collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of the PD-1 and VISTA pathways, including PD-L1/VISTA
antagonist CA-170, and oral small molecule antagonists of the PD-1
and TIM-3 pathways, including PD-L1/TIM-3 antagonist CA-327, as
well as to molecules designed to inhibit the IRAK4 kinase,
including CA-4948. CA-170 is currently undergoing testing in a
Phase 1 trial in patients with advanced solid tumors and lymphomas.
Curis is also party to a collaboration with Genentech, a member of
the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma, and are further developing Erivedge in other diseases
including idiopathic pulmonary fibrosis and myelofibrosis.
For more information, visit Curis's website at
www.curis.com.
Contact:
James E. Dentzer
Chief Financial Officer & Chief Administrative Officer
Curis, Inc.
617-503-6597
jdentzer@curis.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024